巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Orchard Therapeutics plc

    ORTX
    0.601
    0.000
    0.13%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Orchard Therapeutics plc - 延遲價格・最後更新於 12/08 9:30
    最高位
    0.620
    最低位
    0.596
    開市價
    --
    前收市價
    0.600
    成交量(千)
    17.66
    成交額(百萬)
    0.09
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    75.98
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    3.180 - 0.412
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Orchard Therapeutics plc
    證券代碼
    ORTX.US
    所屬板塊
    Biotechnology
    公司業務
    Orchard Therapeutics PLC is a United Kingdom-based commercial-stage, a fully-integrated biopharmaceutical company. The company is engaged in transforming the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. It operates in three geographic regions: the United Kingdom, European Union, and the United States. Orchard Rx is focusing on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, used for the treatment of ADA-SCID five lentiviral product candidates.
    發行量
    125834611
    公司總部
    108 Cannon Street
    公司網址
    https://www.orchard-tx.com
    公司電郵
    renee.leck@orchard-tx.com
    公司電話
    +44 2038088286
    暫無內容

    關於

    Orchard Therapeutics plc(ORTX.US)所屬的行業板塊為Biotechnology。
    Orchard Therapeutics PLC is a United Kingdom-based commercial-stage, a fully-integrated biopharmaceutical company. The company is engaged in transforming the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. It operates in three geographic regions: the United Kingdom, European Union, and the United States. Orchard Rx is focusing on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, used for the treatment of ADA-SCID five lentiviral product candidates.
    詳細公司背景可參考: https://www.orchard-tx.com